Actos (Pioglitazone) Cost in South Dakota: 2026 Prices, Insurance, and Savings

What Does Pioglitazone Actually Cost in South Dakota?

Generic pioglitazone is one of the least expensive diabetes medications available in South Dakota, averaging $15 per month at retail pharmacies across the state. Brand-name Actos carries a $60 monthly list price from Takeda, but fewer than 5% of prescriptions filled nationwide use the brand when a generic is available. The price gap makes the generic version the default choice for nearly every patient and pharmacy.

Prices vary by pharmacy. Walmart, Hy-Vee, and Lewis Drug locations across Sioux Falls, Rapid City, and Aberdeen often price 30-day generic pioglitazone supplies between $4 and $12 on their discount generic lists. Independent pharmacies may charge closer to $18 to $22 without a discount card. The FDA-approved prescribing information for pioglitazone covers doses of 15 mg, 30 mg, and 45 mg tablets, all priced similarly at the generic level.

Prescription discount platforms like GoodRx, RxSaver, and SingleCare can push the price below $10 at participating South Dakota locations. These programs require no insurance and work at most chain pharmacies. A patient paying full retail without any discount or insurance would still spend less than $20 per month in most cases, making pioglitazone one of the most affordable branded-to-generic conversions in endocrinology.

For context, the PIVENS trial (N=247) demonstrated that pioglitazone 30 mg improved histological features of nonalcoholic steatohepatitis over 96 weeks compared to placebo, with 34% of pioglitazone patients achieving the primary endpoint versus 19% on placebo 1. That evidence base supports off-label prescribing for NASH, a use that has grown substantially since 2020, and at $15 per month the cost barrier is minimal.

Does South Dakota Medicaid Cover Pioglitazone?

South Dakota Medicaid does not cover Actos or generic pioglitazone as of 2026. The state's preferred drug list excludes thiazolidinediones entirely. Patients enrolled in South Dakota Medicaid who need pioglitazone face two practical options: pay the $15 cash price out of pocket or request a prior authorization exception, which the state may grant in limited circumstances.

South Dakota's Medicaid program covers roughly 115,000 residents, and the state formulary decisions follow federal Medicaid Drug Rebate Program requirements while retaining flexibility on preferred status. The decision to exclude pioglitazone likely reflects the availability of metformin and sulfonylureas as first-line agents at even lower cost. Metformin remains the foundation of type 2 diabetes pharmacotherapy per the American Diabetes Association Standards of Care, and most state Medicaid programs prioritize it accordingly.

A prior authorization request typically requires documentation that the patient has tried and failed metformin, or has a contraindication such as an eGFR below 30 mL/min/1.73m². The turnaround time for South Dakota Medicaid prior authorizations averages 24 to 72 hours. Providers can submit these electronically through the state's pharmacy benefit manager. Even if denied, the $15 generic cash price is often less than a Medicaid copay for a non-preferred brand in many other states.

Insurance Coverage for Pioglitazone in South Dakota

Most commercial insurance plans in South Dakota place generic pioglitazone on Tier 1 (preferred generic), resulting in copays between $0 and $15. That means insured patients frequently pay the same or less than the cash price. Brand-name Actos typically sits on Tier 3 (non-preferred brand), with copays of $40 to $75.

Sanford Health Plan and Avera Health Plans, the two largest regional insurers in South Dakota, both list generic pioglitazone as a preferred generic without prior authorization requirements. Blue Cross Blue Shield of South Dakota covers generic pioglitazone on its standard formulary as well. Medicare Part D plans vary by carrier, but the Centers for Medicare & Medicaid Services data shows pioglitazone appearing on most Part D formularies at the lowest generic tier.

Patients with high-deductible health plans may pay the full cash price until their deductible is met. In those cases, using a GoodRx or manufacturer discount card instead of running the prescription through insurance can actually lower the out-of-pocket cost and may not count toward the deductible. This is a trade-off worth discussing with a pharmacist. The total annual cost of generic pioglitazone at $15 per month is $180, which falls below most individual deductibles in high-deductible plans.

The Endocrine Society clinical practice guidelines note that pioglitazone provides durable glycemic control with a low risk of hypoglycemia, a profile that supports its formulary placement as a preferred agent. In the PROactive trial (N=5,238), pioglitazone reduced the composite secondary endpoint of all-cause mortality, nonfatal myocardial infarction, and stroke by 16% in patients with type 2 diabetes and macrovascular disease 2. That cardiovascular benefit adds clinical weight to formulary inclusion decisions.

Is Compounded Pioglitazone Legal in South Dakota?

Yes. South Dakota permits 503A compounding pharmacies to prepare pioglitazone formulations with a valid patient-specific prescription. A 503A pharmacy operates under Section 503A of the Federal Food, Drug, and Cosmetic Act and compounds medications based on individual prescriptions rather than in bulk 3.

Compounded pioglitazone may cost $0 to $10 depending on the pharmacy's pricing model. Some compounding pharmacies absorb the cost of inexpensive active ingredients into their dispensing fee. The practical question is why a patient would choose compounded pioglitazone over a $4 to $15 manufactured generic tablet.

There are a few valid reasons. Patients who need a specific dose not available as a manufactured tablet (say, 7.5 mg or 22.5 mg) can get a custom-compounded formulation. Patients with allergies to specific inactive ingredients (dyes, lactose, certain fillers) in the manufactured tablets may also benefit from a compounded version. Pediatric patients who cannot swallow tablets might need a liquid suspension.

South Dakota does not impose additional state-level restrictions on 503A compounding beyond federal requirements. The South Dakota Board of Pharmacy oversees compounding pharmacy licensure. Patients should verify that any compounding pharmacy they use holds a current South Dakota pharmacy license and follows USP 795 standards for non-sterile compounding.

The FDA's compounding quality page outlines the federal framework that applies uniformly across states, including South Dakota. Outsourcing facilities (503B) can also produce pioglitazone without patient-specific prescriptions, but these primarily supply healthcare facilities rather than individual patients.

Telehealth Prescribing of Pioglitazone in South Dakota

South Dakota allows telehealth prescribing of pioglitazone with no geographic restrictions within the state. A provider licensed in South Dakota can evaluate a patient via video or audio visit and prescribe pioglitazone electronically to any South Dakota pharmacy.

The state adopted permanent telehealth parity legislation following the temporary COVID-era expansions. South Dakota Codified Law 36-4-41.1 through 36-4-41.4 governs telehealth practice, and the South Dakota Board of Medical and Osteopathic Examiners recognizes telehealth encounters as valid for establishing a provider-patient relationship.

Because pioglitazone is not a controlled substance, it faces none of the DEA-related telehealth prescribing restrictions that apply to stimulants or opioids. A clinician can prescribe it after a standard evaluation that includes review of the patient's hemoglobin A1c, liver function tests (ALT), and assessment for heart failure risk factors. The FDA label carries a boxed warning for congestive heart failure, so clinicians must screen for NYHA Class III or IV heart failure before prescribing.

Telehealth platforms operating in South Dakota, including HealthRX, can send prescriptions to local pharmacies in Sioux Falls, Rapid City, Brookings, Watertown, Mitchell, and every other city with a licensed pharmacy. Patients in rural parts of western South Dakota, where the nearest endocrinologist may be 100+ miles away, benefit most from this access model. The American Association of Clinical Endocrinology supports telehealth delivery of chronic disease management for conditions like type 2 diabetes.

Manufacturer Savings and Discount Programs

Takeda offers a savings card for brand-name Actos that can reduce copays to as little as $0 for commercially insured patients. The card does not apply to government insurance (Medicare, Medicaid, Tricare). Given that generic pioglitazone already costs $15 or less, the savings card is primarily relevant for the small number of patients whose physicians specifically prescribe brand Actos.

For generic pioglitazone, discount programs provide more practical value. GoodRx coupons bring the price to $4 to $8 at Walmart, Costco, and CVS locations in South Dakota. RxAssist and NeedyMeds maintain databases of patient assistance programs, though pioglitazone's low generic price means few patients qualify for or need manufacturer assistance.

The Mark Cuban Cost Plus Drug Company (CostPlusDrugs.com) lists generic pioglitazone at its standard markup model: cost plus 15% plus a $5 pharmacy fee. For a medication with a wholesale acquisition cost under $3, this results in a final price between $5 and $8 shipped to a South Dakota address. This option works well for patients without a convenient pharmacy or those in remote areas.

South Dakota does not operate a state-level prescription assistance program comparable to those in states like New York (EPIC) or Pennsylvania (PACE). The Health Resources and Services Administration 340B program applies to qualifying health centers and hospitals in South Dakota, and patients receiving care at 340B-covered entities may access pioglitazone at deeply discounted rates. Federally Qualified Health Centers in Sioux Falls, Pine Ridge, and Rapid City participate in the 340B program.

Clinical Considerations That Affect Cost Decisions

Pioglitazone's cost advantage becomes clinically meaningful when comparing it to newer, more expensive diabetes medications. A month of semaglutide (Ozempic) costs $900+ without insurance. Tirzepatide (Mounjaro) runs over $1,000. Even with insurance, these GLP-1 receptor agonists carry copays of $25 to $150 per month on most commercial plans.

The question is whether pioglitazone offers comparable clinical value. For pure glycemic control, pioglitazone typically lowers A1c by 1.0 to 1.5 percentage points, similar to the effect of moderate-dose GLP-1 agonists 4. Pioglitazone does not cause hypoglycemia when used as monotherapy, which distinguishes it from sulfonylureas. It also does not cause the gastrointestinal side effects (nausea, vomiting, diarrhea) common with GLP-1 agonists.

The trade-off is weight. Pioglitazone causes an average weight gain of 2 to 4 kg over 6 to 12 months due to fluid retention and increased subcutaneous adipose tissue. The PROactive study documented mean weight gain of 3.6 kg over 34.5 months in the pioglitazone group 2. For patients already managing obesity alongside diabetes, this side effect creates a meaningful clinical tension.

"Pioglitazone remains a first-line consideration for patients with type 2 diabetes and NAFLD who cannot tolerate or afford GLP-1 receptor agonists," according to the AACE/ACE 2023 Consensus Statement on type 2 diabetes management. The American Diabetes Association's 2024 Standards of Care also list pioglitazone as a recommended agent when cost is a primary barrier to treatment adherence 5.

Liver monitoring deserves mention. The FDA requires a baseline ALT before starting pioglitazone and periodic monitoring thereafter. If ALT exceeds 2.5 times the upper limit of normal, pioglitazone should not be initiated. This lab requirement adds $10 to $30 per test at South Dakota facilities, a minor but real addition to the total cost of therapy.

How South Dakota Compares to Neighboring States

Generic pioglitazone prices are similar across the northern plains. Nebraska, North Dakota, Minnesota, Iowa, Wyoming, and Montana all show average retail prices between $12 and $18 per month for the generic. South Dakota sits in the middle of this range at $15.

The key difference is Medicaid. North Dakota Medicaid covers generic pioglitazone with prior authorization. Minnesota Medical Assistance (Medicaid) covers it as a preferred drug. Iowa Medicaid covers pioglitazone on its preferred drug list. South Dakota's decision to exclude it entirely places it as an outlier among its neighbors 6.

For patients near state borders (Sioux City area, Fargo-Moorhead corridor), the Medicaid coverage question is moot since eligibility is tied to state of residence, not pharmacy location. A South Dakota Medicaid beneficiary cannot fill at a Minnesota pharmacy and receive Minnesota Medicaid coverage. The practical takeaway: South Dakota Medicaid patients should budget $15 per month as an out-of-pocket expense or explore 340B-eligible facilities.